OriGene acquires leading Chinese pathology testing firm

Rockville, MD-based OriGene Technologies has acquired Beijing Zhongshan Golden Bridge Biotechnology Co (ZsBio), establishing OriGene as a provider of pathology testing products to the growing Chinese oncology diagnostic market. ZsBio claims an industry-leading position in the Chinese pathology testing market due to its product portfolio, expertise and strong client relationships, and has established itself in the Chinese pathology diagnostic field. According to OriGene, the Chinese pathology testing market has been experiencing double-digit growth annually and is one of the fast-growing segments of the Chinese diagnostic industry.

This article is tagged to:
Sector: Medical Devices
Geography: China

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.